Johnson & Johnson Experiences Up to date Information From Two Early-Stage A number of Myeloma Research Of Talvey Combo Therapy – Johnson & Johnson (NYSE:JNJ)

On Friday, Johnson & Johnson JNJ launched up to date outcomes from the investigational Part 1b RedirecTT-1 examine evaluating the mixture of Talvey (talquetamab) and Tecvayli (teclistamab) in sufferers with relapsed or refractory a number of myeloma.

At information cutoff, 44 sufferers had been handled with the really helpful part 2 routine (RP2R) of 0.8 mg/kg of Talvey together with 3 mg/kg of Tecvayli each different week.

The general response fee (ORR) was 79.5%, with a whole response or higher (CR+) fee of 52.3%, an 18-month length of response (DOR) of 85.9%, and an 18-month progression-free survival (PFS) fee of 69.8% with a median follow-up of 18.2 months.

Outcomes from a subgroup evaluation of sufferers with extramedullary illness demonstrated an ORR of 61.1%, with a CR+ fee of 33.3%, an 18-month DOR of 81.8%, and an 18-month PFS fee of 52.9% in sufferers with EMD at median follow-up 13.6 months.

Johnson & Johnson additionally revealed up to date outcomes from the investigational Part 1b TRIMM-2 examine evaluating the mixture of Talvey with Darzalex Faspro and pomalidomide in sufferers with relapsed or refractory a number of myeloma that demonstrated an ORR of 82%.

At information cutoff, 77 sufferers had obtained Talvey in doses of 0.4 mg/kg weekly (QW) or 0.8 mg/kg biweekly (Q2W), with step-up doses mixed with Darzalex Faspro and pomalidomide.

Within the QW arm (n=18), the general response fee (ORR) was 100%, with 56 % having a whole response (CR) or higher.

The Q2W arm (n=59) achieved 76% ORR, with 56% reaching CR or higher.

The median length of response (DOR) within the Q2W arm was 26.4 months, and the median progression-free survival (PFS) was 20.3 months.

Outcomes confirmed that 52% of anti-CD38 refractory sufferers (n=64) achieved CR or higher, and 70.8% obtained prior chimeric antigen receptor T cell remedy (n=24) achieved CR or higher.

Sufferers who had obtained prior bispecific antibodies (n=29) achieved an 82.8% ORR.

Value Motion: JNJ inventory is buying and selling 0.83% larger at $162.73 on the final verify on Friday.

Learn Subsequent:

Picture through Shutterstock